Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial.
The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease
inhibitor, in the treatment of radiation-induced acute oral mucositis in localregionally
advanced nasopharyngeal carcinoma(NPC) patients treated with concurrent
chemoradiotherapy(CCRT). To Explore a new and efficient way to reduce the incidence and
severity of radiation-induced acute oral mucositis.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Fifth Affiliated Hospital, Sun Yat-Sen University First People's Hospital of Foshan People's Hospital of Zhongshan